This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis

This study is currently recruiting participants.
See Contacts and Locations
Verified June 2017 by Masonic Cancer Center, University of Minnesota
Sponsor:
Information provided by (Responsible Party):
Masonic Cancer Center, University of Minnesota
ClinicalTrials.gov Identifier:
NCT02171104
First received: June 20, 2014
Last updated: June 15, 2017
Last verified: June 2017
  Purpose
This single-institution, phase II study is designed to test the ability to achieve donor hematopoietic engraftment while maintaining low rates of transplant-related mortality (TRM) using busulfan- and fludarabine-based conditioning regimens with busulfan therapeutic drug monitoring (TDM) for patients with various inherited metabolic disorders (IMD) and severe osteopetrosis (OP).

Condition Intervention Phase
Mucopolysaccharidosis Disorders Hurler Syndrome Hunter Syndrome Maroteaux Lamy Syndrome Sly Syndrome Alpha-Mannosidosis Fucosidosis Aspartylglucosaminuria Glycoprotein Metabolic Disorders Sphingolipidoses Recessive Leukodystrophies Globoid Cell Leukodystrophy Metachromatic Leukodystrophy Niemann-Pick B Niemann-Pick C Subtype 2 Sphingomyelin Deficiency Peroxisomal Disorders Adrenoleukodystrophy With Cerebral Involvement Zellweger Syndrome Neonatal Adrenoleukodystrophy Infantile Refsum Disease Acyl-CoA Oxidase Deficiency D-Bifunctional Enzyme Deficiency Multifunctional Enzyme Deficiency Alpha-methylacyl-CoA Racmase Deficiency Mitochondrial Neurogastrointestingal Encephalopathy Severe Osteopetrosis Hereditary Leukoencephalopathy With Axonal Spheroids (HDLS; CSF1R Mutation) Inherited Metabolic Disorders Biological: Stem Cell Transplantation Drug: IMD Preparative Regimen Drug: Osteopetrosis Only Preparative Regimen Drug: Osteopetrosis Haploidentical Only Preparative Regimen Drug: cALD SR-A (Standard-Risk, Regimen A) Drug: cALD SR-B (Standard-Risk, Regimen B) Drug: cALD HR-D (High-Risk, Regimen C) Drug: cALD HR-D (High-Risk, Regimen D) Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: MT2013-31: Allogeneic Hematopoietic Cell Transplantation for Inherited Metabolic Disorders and Severe Osteopetrosis Following Conditioning With Busulfan (Therapeutic Drug Monitoring), Fludarabine +/- ATG

Resource links provided by NLM:


Further study details as provided by Masonic Cancer Center, University of Minnesota:

Primary Outcome Measures:
  • Percent of subjects who achieve high-level donor hematopoietic engraftment [ Time Frame: Day +42 post-transplant ]
    Defined as neutrophil recovery by Day +42 post-transplant and ≥ 80% donor cells on the myeloid fraction of peripheral blood at Day +100 post-transplant

  • Percent of subjects who achieve high-level donor hematopoietic engraftment [ Time Frame: Day +100 post-transplant ]
    Defined as ≥ 80% donor cells on the myeloid fraction of peripheral blood at Day +100 post-transplant


Secondary Outcome Measures:
  • Graft-versus-host disease [ Time Frame: Day +100 post-transplant ]
    Incidence and severity of GvHD

  • Transplant-related mortality [ Time Frame: Day +100 post-transplant ]
    Incidence of TRM

  • Regimen-related toxicity [ Time Frame: Day +100 post-transplant ]
    Defined as infection, acute renal failure, respiratory failure, cardiac failure, and veno-occlusive disease

  • Post-HSCT changes in disease [ Time Frame: 1 year ]
    Incidence of radiographic, physiologic, neuro-psychologic, and/or biochemical aspects of the disease as assessed on a disease-specific basis

  • Post-HSCT changes in disease [ Time Frame: 2 years ]
    Incidence of radiographic, physiologic, neuro-psychologic, and/or biochemical aspects of the disease as assessed on a disease-specific basis


Estimated Enrollment: 100
Actual Study Start Date: July 10, 2014
Estimated Study Completion Date: September 2019
Estimated Primary Completion Date: September 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: IMD - Except Haplo-identical

Inherited Metabolic Disease (IMD) - Except Haplo-Identical

See intervention descriptions.

Biological: Stem Cell Transplantation
Infusion given on Day 0
Drug: IMD Preparative Regimen
  • Anti-thymocyte Globulin (ATG)
  • Fludarabine
  • Busulfan
Experimental: OP - Except Haplo-Identical

Severe Osteoperosis (OP) - Except Haplo-Identical

See intervention descriptions.

Biological: Stem Cell Transplantation
Infusion given on Day 0
Drug: Osteopetrosis Only Preparative Regimen
  • Anti-thymocyte Globulin (ATG)
  • Fludarabine
  • Busulfan
  • Thiotepa
Experimental: OP and IMD -Haplo-Identical Only

Severe Osteopetrosis (OP) and Inhterited Metabolic Disorders (IMD)

-Haplo-Identical Only

See intervention descriptions.

Biological: Stem Cell Transplantation
Infusion given on Day 0
Drug: Osteopetrosis Haploidentical Only Preparative Regimen
  • Rituximab
  • Alemtuzumab
  • Busulfan
  • Fludarabine
Experimental: cALD SR-A (Standard-Risk, Regimen A)
See intervention descriptions.
Biological: Stem Cell Transplantation
Infusion given on Day 0
Drug: IMD Preparative Regimen
  • Anti-thymocyte Globulin (ATG)
  • Fludarabine
  • Busulfan
Drug: cALD SR-A (Standard-Risk, Regimen A)
N-acetylcysteine start day +1 through day +28
Experimental: cALD SR-B (Standard-Risk, Regimen B)
See intervention descriptions.
Biological: Stem Cell Transplantation
Infusion given on Day 0
Drug: IMD Preparative Regimen
  • Anti-thymocyte Globulin (ATG)
  • Fludarabine
  • Busulfan
Drug: cALD SR-B (Standard-Risk, Regimen B)
N-acetylcysteine start day +1through day +56
Experimental: cALD HR-C (High-Risk, Regimen C)
See intervention descriptions.
Biological: Stem Cell Transplantation
Infusion given on Day 0
Drug: IMD Preparative Regimen
  • Anti-thymocyte Globulin (ATG)
  • Fludarabine
  • Busulfan
Drug: cALD HR-D (High-Risk, Regimen C)
N-acetylcysteine and celecoxib start day of admission (prior to conditioning regimen) and continue through day +100
Experimental: cALD HR-D (High-Risk, Regimen D)
See intervention descriptions.
Biological: Stem Cell Transplantation
Infusion given on Day 0
Drug: IMD Preparative Regimen
  • Anti-thymocyte Globulin (ATG)
  • Fludarabine
  • Busulfan
Drug: cALD HR-D (High-Risk, Regimen D)
N-acetylcysteine, celecoxib, vitamin E and alpha lipoic acid start day of admission (prior to conditioning regimen) and continue through day +100

  Eligibility

Ages Eligible for Study:   up to 55 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 0 through 55 years of age
  • Adequate graft available
  • Adequate organ function
  • Eligible Diseases:

    • Mucopolysaccharidosis Disorders:

      • MPS IH (Hurler syndrome)
      • MPS II (Hunter syndrome) if the patient has no or minimal evidence of symptomatic neurologic disease but is expected to have a neurologic phenotype
      • MPS VI (Maroteaux-Lamy syndrome)
      • MPS VII (Sly syndrome)
    • Glycoprotein Metabolic Disorders:

      • Alpha mannosidosis
      • Fucosidosis
      • Aspartylglucosaminuria
    • Sphingolipidoses and Recessive Leukodystrophies:

      • Globoid cell leukodystrophy
      • Metachromatic leukodystrophy
      • Niemann-Pick B patients (sphingomyelin deficiency)
      • Niemann-Pick C subtype 2
    • Peroxisomal Disorders:

      • Adrenoleukodystrophy with cerebral involvement
      • Zellweger syndrome
      • Neonatal Adrenoleukodystrophy
      • Infantile Refsum disease
      • Acyl-CoA-Oxidase Deficiency
      • D-Bifunctional enzyme deficiency
      • Multifunctional enzyme deficiency
      • Alpha-methylacyl-CoA Racmase Deficiency (AMACRD)
      • Mitochondrial Neurogastrointestingal Encephalopathy (MNGIE)
    • Severe Osteopetrosis (OP)
    • Hereditary Leukoencephalopathy with axonal spheroids (HDLS; CSF1R mutation)
    • Other Inherited Metabolic Disorders (IMD): Patients will also be considered who have other lifethreatening, rare lysosomal, peroxisomal or other similar inherited disorders characterized by white matter disease or other neurologic manifestations for which there is rationale that transplantation would be of benefit, such as certain patients with Wolman's disease, GM1 gangliosidosis, I-cell disease, Tay-Sachs disease, Sandhoff disease or others.
    • Voluntary written consent

Exclusion Criteria:

  • Pregnancy - menstruating females must have a negative serum or urine pregnancy test within 14 days of study treatment start
  • Prior myeloablative chemotherapy exposure within 4 months of the start of conditioning on this protocol (patients excluded for this reason may be eligible for other institutional protocols)
  • Uncontrolled bacterial, fungal or viral infections including HIV (including active infection with Aspergillus or other mold within 30 days)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02171104

Contacts
Contact: Kim Nelson 612-273-2925 knelso62@fairview.org

Locations
United States, Minnesota
Masonic Cancer Center, University of Minnesota Recruiting
Minneapolis, Minnesota, United States, 55455
Contact: Kim Nelson    612-273-2925    knelso62@fairview.org   
Sponsors and Collaborators
Masonic Cancer Center, University of Minnesota
Investigators
Principal Investigator: Weston Miller, MD Masonic Cancer Center, University of Minnesota
  More Information

Responsible Party: Masonic Cancer Center, University of Minnesota
ClinicalTrials.gov Identifier: NCT02171104     History of Changes
Other Study ID Numbers: 2013LS104
Study First Received: June 20, 2014
Last Updated: June 15, 2017

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by Masonic Cancer Center, University of Minnesota:
allogeneic hematopoietic cell transplantation
bone marrow transplantation
IMD
AMACRD
MNGIE
HDLS
OP
ALD

Additional relevant MeSH terms:
Disease
Syndrome
Brain Diseases
Mucopolysaccharidoses
Metabolic Diseases
Mucopolysaccharidosis II
Adrenoleukodystrophy
Leukodystrophy, Metachromatic
Leukoencephalopathies
Osteopetrosis
Mannosidase Deficiency Diseases
alpha-Mannosidosis
Mucopolysaccharidosis I
Leukodystrophy, Globoid Cell
Sphingolipidoses
Mucopolysaccharidosis VI
Peroxisomal Disorders
Mucopolysaccharidosis VII
Fucosidosis
Aspartylglucosaminuria
Zellweger Syndrome
Refsum Disease, Infantile
Refsum Disease
Intestinal Pseudo-Obstruction
Mitochondrial Encephalomyopathies
Hearing Loss, Sensorineural
Gonadal Dysgenesis, 46,XX
Pathologic Processes
Central Nervous System Diseases
Nervous System Diseases

ClinicalTrials.gov processed this record on July 24, 2017